Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY). (2021)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1111/bjh.17073
PubMed Identifier: 32926420
Publication URI: http://europepmc.org/abstract/MED/32926420
Type: Journal Article/Review
Volume: 193
Parent Publication: British journal of haematology
Issue: 1
ISSN: 0007-1048